BUFFALO, N.Y., July 8, 2013 /PRNewswire/ -- Kinex Pharmaceuticals (Kinex), a leading specialty biotech focused on the development and commercialization of next generation oral therapies for cancer diseaseshas appointed Flint D. Besecker to its Executive Team as Chief Financial Officer and Executive Vice President. In this newly created position, Mr. Besecker will have primary responsibility over all non-scientific aspects of Kinex reporting to Kinex's Chief Executive Officer, Dr. Johnson Lau. Flint has been an investor and Board Director of Kinex since 2011.
Mr. Besecker's appointment further underscores Kinex's strategy of evolving into a successful global drug development company with operations in the United States and in Asia. "Flint's diverse and successful business experience in the healthcare industry is an ideal fit for the next stage of Kinex's evolution. He has significant experience in capital markets and strategy having worked for such esteem companies as GE Healthcare Financial Services and as founder and President of CIT Healthcare; both fortune 500 companies. He also has experience in a public company environment having led Care Investment Trust's initial public offering and listing on the New York Stock Exchange," Dr.Johnson Lau said. "We are excited to have Flint join our Executive Team with his depth of experience and strong track record building value for shareholders."
Mr. Besecker commented, "I am thrilled to join the Kinex Team working collaboratively with its highly skilled scientists, advisors and drug development partners throughout the globe to drive significant value for all of our key stakeholders. Cancer is a devastating disease and a major healthcare burden both in the U.S. and globally and I am pleased to work with a top notch team combating this major global health issue."
Mr. Besecker is a 20-year veteran of the healthcare industry, bringing a wealth of experience in all facets of healthcare. He currently runs Firestone Asset Management, a private investment and advisory firm in the healthcare industry. He is also Vice Chairman of the Board of Ameris Acquisitions, LLC a private Nashville Tennessee hospital company. His previous roles included CEO of the Center for Hospice and Palliative Care, Founder of Care Investment Trust, founder of CIT Healthcare, Managing Director of GE Healthcare Financial Services and Chief Risk Officer of Heller Healthcare. He has also held numerous Board positions in both private and public healthcare companies and is a former CPA in New York State.
Founded in 2004, Kinex is led by a strong, experienced Management Team and Board of Directors with a track record of achieving value-creating milestones and cumulative experience of over 250 years in both the pharmaceutical and biotechnology industries. This includes the filing of more than 11 NDAs and 20 INDs with the Food and Drug Administration and the development of more than 10 marketed products, including a number of blockbusters. Kinex has utilized the proprietary platform technologies Mimetica, Opal, and Orascovery to discover new compounds and to build a pipeline of drug candidates with unique mechanisms that address unmet medical needs with large market potential. With offices in both Buffalo NY and Hong Kong, Kinex has numerous existing partnerships in Asia and New Zealand and investors throughoutthe United States and Asia.
701 Ellicott Street
Buffalo, NY 14203
SOURCE Kinex Pharmaceuticals